ABOUT US

We invest in pharmaceutical, medical device and other healthcare companies. We deploy a significant amount of our own capital and we access further capital as needed. We are active investors and generally invest only when we believe that we can contribute to management through an active engagement at the board level. We draw upon our significant and diversified backgrounds as executives, entrepreneurs, bankers and lawyers. We add value to the companies we invest in, far beyond the capital we contribute.

 

OUR FOCUS

  • Pharmaceutical and med-tech companies on the forefront of technological advancement.
  • Differentiated products or technologies with the potential to address significant unmet medical need.
  • Companies with less than $50 million in revenues.
  • We invest across the development cycle, with a preference for companies with approved products or services, maximizing the value-add we bring to the commercialization effort.
  • Particular focus on European companies with a need to penetrate the US market.
  • Opportunity to deploy our capital and to contribute with our operational management experience and expertise.
  • Active owners seeking meaningful board representation.

HOW WE OPERATE

  • Providing c-suite operational, legal and financial support.
  • Actively participating in strategy formulation and closely monitoring its execution.
  • Establishing processes, structures, and skills enabling competitive advantages.
  • Stimulate and lead thinking around go-to-market commercial models with a particular focus on the US, EU 5, China and Japan. This includes sales force deployment, strategic pricing & market access, messaging, and ongoing tracking of performance indicators.
  • Ensuring robust governance and high-quality management through our involvement.

INVESTMENT

In October 2023, we acquired control of IRRAS AB, a Swedish medical device company headquartered in San Diego. For more information, visit irras.com.

PARTNERS

Michel_Pettigrew

Michel Pettigrew

Michel Pettigrew boasts an impressive career spanning more than four decades in the Pharmaceutical Industry. His extensive track record includes roles as Executive Chairman of SEVER Life Sciences BV, Executive Chairman of Ferring Holding Inc., and 14 years as President of Ferring Holding. Prior to this, Michel held several senior positions at Bristol-Myers Squibb. Currently, he is Chairman of the Board of Sunstar SA, a family-owned Oral Care company; Board member of Hovione AG, a family-owned CDMO;
Agora Care, a Geneva based Med-tech startup; and IRRAS Holding Inc.
Olof_Clausson

Olof Clausson

Olof Clausson, a US corporate lawyer and former partner of Latham & Watkins LLP. Based in London, Olof was one of Europe’s leading capital markets lawyers. Among many high-profile engagements, he advised the Government of Singapore Corporation (GIC) on its CHF 13 billion investment in UBS. He assisted Ericsson on its SEK 30 billion rights offering, and Nordea on its €3 billion rights offering. Between 2016 and 2019, he acted on 5 of Europe’s 20 largest IPOs. Currently, he is a Board member of IRRAS Holding Inc.
Martin_Bjaringer

Martin Bjaringer

Martin Bjaringer, is an entrepreneur and investor with a track record of successful investments spanning decades. Martin started out as an investment banker at Alfred Berg, and early on he became an influential investor in the Swedish market. He was a controlling shareholder in Protect Data, a Swedish security software company eventually sold to Check Point Software Technologies. He is a founder of Monterro, a Swedish private equity manager focused on B2B software acquisitions. Currently, he serves on the Board of Formpipe AB, a software company listed on Nasdaq Stockholm.
Aaron_Graff

Aaron Graff

Aaron Graff’s global executive career spans primary care and specialty pharmaceuticals, non-prescription (OTC) medicines, and health and beauty aids (HBA) across multiple therapeutic areas, distribution channels and geographies. He worked in consumer product brand management for International Playtex and spent 17 years at Bristol-Myers Squibb in a variety of commercial positions in both the USA and Europe. After 22 years at Ferring Group, Aaron retired as Ferring Group Executive Committee member and Executive Chairman Ferring USA. Currently Aaron is an active board member of Nordic Pharma USA and the American Institute for Stuttering. He is a proud supporter of Community Hope and a mentor to executives considering global career paths.

Eva Crone

Business operations & Investor contact

eva@legacycapitalpartners.eu

Mailing adress

51-53 Rue de Merl, PO.Box 621,
L-2016 Luxembourg
Legacy Capital Partners G.P Sàrl

LET’S WORK TOGETHER

Empowering Innovation, and Transforming Healthcare.